Fundraising Fox
/Companies
Sign in

Algeta

Unicorn exit · $2.9Bacquired by Bayer

2 known investors

Find your way into Algeta

Acquired by Bayer AG December 2013 · $2.9B ($2.9 billion (48% premium to pre-announcement share price)) · source ↗

Algeta was a Norwegian oncology company developing alpha-particle radiopharmaceuticals, notably Xofigo (radium-223 dichloride) for bone metastases in prostate cancer.

Investors · 2

Birk Venturelisted by Birk VentureOslo

How we know: Birk Venture's portfolio page · Not right? Tell us

In the news

Bayer raises offer for Xofigo partner Algeta - PharmaTimespharmatimes.com · Dec 2013Bayer AG Secures Cancer Firm Algeta With Raised $2.9 Billion Bid - BioSpacebiospace.com · Dec 2013CORRECTED-Bayer raises bid for Norway cancer drug firm Algeta to $2.9 bln | Reutersreuters.com · Dec 2013Algeta Raises $35 Million PIPEventurecapitaljournal.com · Feb 2009Algeta raises USD 35 million (NOK 245 million) in a Private Placement | Fierce Biotechfiercebiotech.com · Feb 2009Advent Venture Partners' portfolio company Algeta raises NOK 250 million in successful offering | Advent Life Sciencesadventls.com · Mar 2007

Frequently asked questions

What does Algeta do?
Algeta was a Norwegian oncology company developing alpha-particle radiopharmaceuticals, notably Xofigo (radium-223 dichloride) for bone metastases in prostate cancer.
Who are Algeta's investors?
Algeta's investors include Advent Life Sciences, Birk Venture.
Who acquired Algeta?
Algeta was acquired by Bayer.